Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab After Combined Modality Therapy in High Risk Anal Cancer
NCT03233711Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2018
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in anal cancer comparing Arm A (nivolumab) with Arm B (clinical observation) (2 arms). Primary endpoint: Disease-Free Survival at 7 years. Started Jul 2018; status: active, not recruiting.
02
Drugs
03
Conditions
anal cancer
Beyond the preview
Go deeper on NCT03233711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233711.